Get the Stockscreener App
11.64
5.60%
-0.69
After Hours:
11.57
-0.07
-0.60%
Intellia Therapeutics Inc stock is traded at $11.64, with a volume of 6.80M.
It is down -5.60% in the last 24 hours and up +24.09% over the past month.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$12.33
Open:
$12.02
24h Volume:
6.80M
Relative Volume:
1.43
Market Cap:
$1.21B
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-2.1241
EPS:
-5.48
Net Cash Flow:
$-382.65M
1W Performance:
-8.92%
1M Performance:
+24.09%
6M Performance:
+12.79%
1Y Performance:
-55.59%
1-Day Range:
$11.46
$12.28
1-Week Range:
$11.46
$13.73
52-Week Range:
$5.90
$26.63
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.64 | 1.28B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Leading CRISPR Pioneer Intellia Therapeutics Announces Q2 2025 Financial Results Date - Stock Titan
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates | NTLA Stock News - GuruFocus
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates - GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates - GlobeNewswire
Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN - TipRanks
Regeneron and Intellia’s Promising Phase 3 Study on NTLA-2001 for ATTR-CM - TipRanks
Candlestick Reversal Detected on Intellia Therapeutics Inc.’s ChartWeekly Stock Watch With Growth Focus Expanded - metal.it
Intellia Therapeutics Inc. Inches Above Key Support — Safe to HoldReliable Investment Entry Signals Confirmed by Charts - metal.it
Published on: 2025-07-28 18:35:59 - metal.it
Stocks To Watch: Intellia Therapeutics Sees Relative Strength Rating Rise To 80 - MSN
Why is Intellia Therapeutics Inc. stock attracting strong analyst attentionOutstanding capital appreciation - jammulinksnews.com
What is the risk reward ratio of investing in Intellia Therapeutics Inc. stockUnlock exclusive trading strategies for gains - jammulinksnews.com
Gene Editing Market Exclusive Report with Detailed Study - openPR.com
What are Intellia Therapeutics Inc. company’s key revenue driversMarket Forecast Outlook With Proven Results - jammulinksnews.com
How Efficient Is Intellia Therapeutics Inc. at Controlling Operating CostsTop Performing Stocks - metal.it
Is Intellia Therapeutics Inc. a growth stock or a value stockInvest in stocks with strong fundamentals - jammulinksnews.com
Does Intellia Therapeutics Inc. stock perform well during market downturnsCapitalize on trading strategies that deliver - jammulinksnews.com
Intellia Shares Drop As Pipeline Bets Face Pivotal Trials - Finimize
Intellia Therapeutics EVP Dulac Edward J III Sells 7462 Shares for $14.02 Each. - AInvest
NTLA CFO Sells 7,462 Shares in Tax Withholding Transaction – Form 4 | YGMZ SEC FilingForm 6-K - Stock Titan
What analysts say about Intellia Therapeutics Inc. stockSuperior risk-adjusted returns - PrintWeekIndia
Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - The Globe and Mail
Intellia Therapeutics Inc. Stock Analysis and ForecastHigh-yield market plays - Autocar Professional
What drives Intellia Therapeutics Inc. stock priceTremendous financial leverage - PrintWeekIndia
Will Intellia Therapeutics Inc. stock benefit from interest rate changesHigh-yield capital appreciation - jammulinksnews.com
What makes Intellia Therapeutics Inc. stock attractive to long term investorsHigh-yield capital appreciation - jammulinksnews.com
Is Intellia Therapeutics Inc. a good long term investmentExtraordinary earning power - Autocar Professional
How high can Intellia Therapeutics Inc. stock price go in 2025Accelerated financial growth - jammulinksnews.com
Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options - Nasdaq
Intellia Therapeutics: A High-Volatility, High-Reward Play in the CRISPR Revolution - AInvest
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At ‘Buy’ (NTLA) - Seeking Alpha
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):